NY-PYRAMID-ANALYTICS
Despite accelerated digital transformation of businesses over the past two years, almost one-third of companies surveyed for a Data & Analytics and Data Platforms study have yet to fully embrace a data-driven approach to strategic decision-making. A new Business Impact Brief commissioned by Pyramid Analytics from 451 Research, part of S&P Global Market Intelligence, states that the emerging discipline of Decision Intelligence could help improve business performance by placing data-driven decision-making within the reach of more personnel within an organization. This means decisions can be made by individuals beyond those who are proficient or skilled in interpreting information and crunching it for insights.
Key Points:
- Almost one-third (32%) of companies have yet to fully embrace a data-driven approach to strategic decision-making, according to 451 Research’s Voice of the Enterprise: Data & Analytics, Data Platforms 2021 survey. That means a sizable number of organizations are missing out on the benefits of utilizing data as a decision-making tool.
- Not all DI platforms provide the same functionality or meet the same needs. Companies should choose Decision Intelligence platforms with rigorous data management and a wide array of analytical functions.
- Decision intelligence requires new software which includes AI and machine learning.
- AI puts the “intelligence” into Decision Intelligence, lowering the skills barrier by automating the complex steps required for a data-driven approach.
- Download the 451 Research report Decision Intelligence: A New Enabler for Data-Driven Decisions [Ungated].
- Click here to schedule a demo of the Pyramid Decision Intelligence Platform .
When an organization effectively uses data to make decisions, it can lead to increased sales, improved business agility, better customer service and engagement, and empowered internal decision-makers. Decision Intelligence: A New Enabler for Data-Driven Decisions is available exclusively from Pyramid Analytics.
Complete, Unified Decision Intelligence
Only the Pyramid Decision Intelligence Platform unifies Data Preparation, Business Analytics, and Data Science on a single, integrated platform. This eliminates the need to use multiple disparate tools and the associated license cost and management complexity. Lower Total Cost of Ownership (TCO), rapid rollout, quicker and direct access to all available data, and industry-leading user adoption means faster time to value. The Pyramid Decision Intelligence Platform can be deployed on-premises, into a private or public cloud, embedded into other apps or delivered through Managed Services Providers (MSP).
Pyramid’s Decision Intelligence strategy was described as evolutionary in a recent analyst report. Pyramid Analytics Plants Stake in Decision Intelligence Ground , authored by Krishna Roy, Senior Research Analyst on the Data, AI & Analytics team at 451 Research, examines Pyramid’s Decision Intelligence Platform in the context of the emerging decision intelligence market which experts see as the next evolution in analytics and business intelligence (ABI).
Quotes
Krishna Roy
, Senior Research Analyst for the Data, AI & Analytics team, 451 Research, part of S&P Global Market Intelligence:
“Decision intelligence is still in its infancy. But its potential to support digital transformation by increasing the levels of data-driven decision-making in an organization is significant. Increased sales, improved business agility, enhanced customer service and engagement, and more empowered and aligned internal decision-makers can all be achieved when data-driven decision-making is effectively implemented. Decision intelligence platforms are likely to play a key role in enabling organizations to realize these benefits.”
Chas Kielt , Vice President of Global Corporate Communications and Partner Marketing, Pyramid Analytic s: “Decision Intelligence is emerging technology that meets all traditional BI and Analytics needs, but delivers accessibility, performance, context, scalability and rich functionality that greatly surpasses legacy tools. Slapping a decision intelligence label on a limited data visualization point product doesn’t make it so. With this report, the 451 Research team is helping data scientists, data analysts, and data-minded business professionals understand the Decision Intelligence market landscape.”
About Pyramid Analytics
Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for everyone to make faster, more informed decisions. It provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. Decision Intelligence Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo.
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Learn more at Pyramid Analytics .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005316/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cross-Border Private Credit Set to Surge, But Operational Complexity Threatens Momentum, CSC Finds4.12.2025 14:30:00 CET | Press release
79% of GPs expect cross-border private credit deals to grow over the next three years, with more than half forecasting rapid acceleration40% of LPs rejected private credit investment opportunities last year due to reporting or operational concerns92% of LPs say specialist outsourcing enhances transparency Cross-border private credit transactions are poised for strong growth, yet operational complexity is emerging as a critical hurdle. According to CSC, the leading provider of business administration and compliance solutions, an overwhelming 92% of limited partners (LPs) express concern over the complexity of these deals. Published in CSC’s latest report, Private Credit 2025: Global Strategies for a $1.5 Trillion Market, the findings highlight a growing disconnect between investors and fund managers as private credit continues its rapid international expansion. 1 While both LPs and general partners (GPs) remain optimistic about the growth of cross-border private credit, they diverge sha
Pace selected by Prudential Financial to help automate its insurance operations with agentic AI4.12.2025 14:15:00 CET | Press release
Pace’s AI-powered agents are helping to streamline policy service and perform other quality assurance tasks within Prudential’s Individual Life Insurance business Pace, the agentic workforce for insurance, was chosen by Prudential’s Individual Life Insurance (ILI) business to help simplify and improve its service delivery. Pace’s AI-powered agents are now streamlining policy servicing and supporting quality assurance efforts within Prudential’s ILI business. The first set of automated systems is now live taking on thousands of hours of work. “Our work with Prudential is an example of how AI can be used as a strategic advantage,” said Pace CEO Jamie Cuffe. “We’re thrilled to support their exceptional team with AI agents in production today that deliver best-in-class accuracy and speed at significant scale.” This multi-year agreement between Pace and Prudential’s ILI business began as a pilot and quickly moved to full production after demonstrating clear improvements in speed and operati
Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment4.12.2025 14:00:00 CET | Press release
OXTEND-03™ (NCT06930625) is a Phase III, multi-center, randomized trial assessing the efficacy and safety of Debio 4126, the first and only octreotide formulation designed for quarterly (3-month) dosing Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company committed to establishing tomorrow’s standards of care in oncology and rare diseases, today announced that the first patient has been randomized in the OXTEND-03™ clinical trial. This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in adults with acromegaly who are currently maintained on somatostatin analogs. OXTEND-03™ is a global trial spanning approximately 75 sites across 21 countries, aiming to enroll around 120 patients. The primary goal of the trial is to confirm Debio 4126’s ability to maintain biochemical control of the disease while significantly
Visa Launches Global Art Collection to Elevate Creators and Celebrate the FIFA World Cup 26™4.12.2025 14:00:00 CET | Press release
Visa spotlights global illustrators and creative small businesses, teaming up with Pharrell Williams’ JOOPITER to accelerate creator growth. Visa today unveiled the first five pieces in its first-ever global art collection celebrating the cultural energy of the FIFA World Cup 26™. Featuring more than twenty artists from six continents, the collection reflects Visa’s belief that creativity drives commerce—and that today’s creators are the entrepreneurs shaping communities and culture around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204080105/en/ Darien Birks (Global) Visa debuted the first five pieces in the collection at an exclusive Miami showcase, “The Art of the Draw”, hosted by multidisciplinary creator KidSuper. The showcase featured the works of artists Darien Birks, Nathan Walker, Cesar Canseco, Ivan Roque, and Rafael Mayani that celebrate the culture and traditions of each host country and host cit
Parse Biosciences Launches Evercode Whole Blood Fixation4.12.2025 14:00:00 CET | Press release
New fixation method streamlines blood sample handling for translational research Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercode™ Whole Blood Fixation, a new kit that enables immediate fixation of whole blood directly at the point of collection. The technology eliminates the need for on-site PBMC isolation, specialized equipment, or trained personnel, allowing translational hematology and pharmaceutical research teams to seamlessly collect blood samples in real-world clinical settings for downstream single cell analysis. Traditional single cell RNA profiling workflows done in a translational setting require a compromise between processing fresh samples, which degrade rapidly and demand skilled handling, and using fixation approaches that capture only a partial transcriptome and cannot provide paired TCR sequences. Fresh PBMC isolation also requires complex workflows and specialized reagents. Everc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom